Business Wire

NSHIFT

7.8.2024 12:44:28 CEST | Business Wire | Press release

Share
nShift: Retailers Urged to Learn Lessons From Summer Sales Season

A failure to master the omnichannel experience may have dented the success of summer sales, a new report suggests. nShift argues that retailers must learn lessons from the summer and apply these lessons to Black Friday and Christmas preparations. To do this well, they need a paradigm shift in how they think about deliveries.

nShift is the global leader in delivery and experience management (DMXM). It leads the way in post-purchase experience management and multi-carrier shipping software. In a new report, “Learning from summer sales” nShift explores how retailers would like to do better at:

  1. Mastering the omnichannel experience – by facilitating ways for online and instore to work together, retailers can compete for a bigger slice of the bargain-hunting pie during major sales events
  2. Focus on customer loyalty – many retailers believe they missed opportunities to build stronger connections with customers. Anything that retailers can do to create a positive experience with first-time customers opens the door to a longer-term relationship
  3. Learning from data – part of the problem is that a great deal of relevant data from the delivery process sits in different systems and sometimes, different organizations
  4. Delivering scale and capacity – some 85% of online shoppers claim that a poor delivery experience would prevent them from ordering from that retailer again.1 But during periods of high demand, some retailers struggle to deliver
  5. International shipping - online shoppers increasingly expect to buy from retailers located anywhere in the world. It’s crucial that warehouses can easily ship beyond borders and keep shoppers up to date with the status of their delivery

Sean Sherwin-Smith, post-purchase product director at nShift, said: “By reflecting on what did and didn’t work well during the summer sales season, retailers can make changes ahead of the all-important ‘peak season’ toward the end of the year. The final months of 2024, which include Singles’ Day, Black Friday and the Christmas shopping season represent a huge sales opportunity for retailers. It’s often where they make the majority of their profits.

“Too often, retailers ignore how the delivery experience can help them boost their performance. Deliveries are typically dismissed as a solely logistical consideration – a world of boxes and parcels. In reality, deliveries hold the keys to unlocking customer loyalty, increasing revenue and improving operations. Creating the right delivery experience will be essential to reaching peak performance.”

The report shows how delivery & experience management (DMXM) with nShift should be central to learning the lessons from summer sales and applying them to peak-season strategies. It combines the core components of delivery management, such as a library of 1000+ carrier connections, with customer-facing applications that manage checkout and returns interfaces and customer communications. This makes it possible for retailers to create a connected delivery experience from checkout to doorstep.

Read the full report “Learning from summer sales: how delivery & experience management (DMXM) can help retailers perfect their peak-season offer by applying lessons from June discounts

nShift. Worry less. Ship smarter. www.nshift.com

1 https://www.ipsos.com/en/ecommerce-marketplaces-delivery-experience

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807365966/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye